Implication of hepatokines in metabolic disorders and cardiovascular diseases

Tae Woo Jung; Hye Jin Yoo; Kyung Mook Choi

doi:10.1016/j.bbacli.2016.03.002

Implication of hepatokines in metabolic disorders and cardiovascular diseases

Tae Woo Jung, Hye Jin Yoo, Kyung Mook Choi

Department of Biomedical Sciences

Research output: Contribution to journal › Review article › peer-review

50 Citations (Scopus)

Abstract

The liver is a central regulator of systemic energy homeostasis and has a pivotal role in glucose and lipid metabolism. Impaired gluconeogenesis and dyslipidemia are often observed in patients with nonalcoholic fatty liver disease (NAFLD). The liver is now recognized to be an endocrine organ that secretes hepatokines, which are proteins that regulate systemic metabolism and energy homeostasis. Hepatokines are known to contribute to the pathogenesis of metabolic syndrome, NAFLD, type 2 diabetes (T2DM), and cardiovascular diseases (CVDs). In this review, we focus on the roles of two major hepatokines, fetuin-A and fibroblast growth factor 21 (FGF21), as well as recently-redefined hepatokines, such as selenoprotein P, angiopoietin-like protein 4 (ANGPTL4), and leukocyte cell-derived chemotaxin 2 (LECT2). We also assess the biology and molecular mechanisms of hepatokines in the context of their potential as therapeutic targets for metabolic disorders and cardiovascular diseases.

Original language	English
Pages (from-to)	108-113
Number of pages	6
Journal	BBA Clinical
Volume	5
DOIs	https://doi.org/10.1016/j.bbacli.2016.03.002
Publication status	Published - 2016 Jun 1

Keywords

Angiopoietin-like protein 4
Fetuin-A
Fibroblast growth factor 21
Hepatokine
Leukocyte cell-derived chemotaxin 2
Selenoprotein P

ASJC Scopus subject areas

Pathology and Forensic Medicine
Molecular Medicine
Physiology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bbacli.2016.03.002

Cite this

@article{a88602f7c66947e1b9aeb9b1397d08a1,

title = "Implication of hepatokines in metabolic disorders and cardiovascular diseases",

abstract = "The liver is a central regulator of systemic energy homeostasis and has a pivotal role in glucose and lipid metabolism. Impaired gluconeogenesis and dyslipidemia are often observed in patients with nonalcoholic fatty liver disease (NAFLD). The liver is now recognized to be an endocrine organ that secretes hepatokines, which are proteins that regulate systemic metabolism and energy homeostasis. Hepatokines are known to contribute to the pathogenesis of metabolic syndrome, NAFLD, type 2 diabetes (T2DM), and cardiovascular diseases (CVDs). In this review, we focus on the roles of two major hepatokines, fetuin-A and fibroblast growth factor 21 (FGF21), as well as recently-redefined hepatokines, such as selenoprotein P, angiopoietin-like protein 4 (ANGPTL4), and leukocyte cell-derived chemotaxin 2 (LECT2). We also assess the biology and molecular mechanisms of hepatokines in the context of their potential as therapeutic targets for metabolic disorders and cardiovascular diseases.",

keywords = "Angiopoietin-like protein 4, Fetuin-A, Fibroblast growth factor 21, Hepatokine, Leukocyte cell-derived chemotaxin 2, Selenoprotein P",

author = "Jung, {Tae Woo} and Yoo, {Hye Jin} and Choi, {Kyung Mook}",

note = "Funding Information: The present work was supported by a grant from the Korean Health Technology R&D Project , Ministry of Health & Welfare , Republic of Korea ( HI14C0133 ). Publisher Copyright: {\textcopyright} 2016 The Authors.",

year = "2016",

month = jun,

day = "1",

doi = "10.1016/j.bbacli.2016.03.002",

language = "English",

volume = "5",

pages = "108--113",

journal = "BBA Clinical",

issn = "2214-6474",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Implication of hepatokines in metabolic disorders and cardiovascular diseases

AU - Jung, Tae Woo

AU - Yoo, Hye Jin

AU - Choi, Kyung Mook

N1 - Funding Information: The present work was supported by a grant from the Korean Health Technology R&D Project , Ministry of Health & Welfare , Republic of Korea ( HI14C0133 ). Publisher Copyright: © 2016 The Authors.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The liver is a central regulator of systemic energy homeostasis and has a pivotal role in glucose and lipid metabolism. Impaired gluconeogenesis and dyslipidemia are often observed in patients with nonalcoholic fatty liver disease (NAFLD). The liver is now recognized to be an endocrine organ that secretes hepatokines, which are proteins that regulate systemic metabolism and energy homeostasis. Hepatokines are known to contribute to the pathogenesis of metabolic syndrome, NAFLD, type 2 diabetes (T2DM), and cardiovascular diseases (CVDs). In this review, we focus on the roles of two major hepatokines, fetuin-A and fibroblast growth factor 21 (FGF21), as well as recently-redefined hepatokines, such as selenoprotein P, angiopoietin-like protein 4 (ANGPTL4), and leukocyte cell-derived chemotaxin 2 (LECT2). We also assess the biology and molecular mechanisms of hepatokines in the context of their potential as therapeutic targets for metabolic disorders and cardiovascular diseases.

AB - The liver is a central regulator of systemic energy homeostasis and has a pivotal role in glucose and lipid metabolism. Impaired gluconeogenesis and dyslipidemia are often observed in patients with nonalcoholic fatty liver disease (NAFLD). The liver is now recognized to be an endocrine organ that secretes hepatokines, which are proteins that regulate systemic metabolism and energy homeostasis. Hepatokines are known to contribute to the pathogenesis of metabolic syndrome, NAFLD, type 2 diabetes (T2DM), and cardiovascular diseases (CVDs). In this review, we focus on the roles of two major hepatokines, fetuin-A and fibroblast growth factor 21 (FGF21), as well as recently-redefined hepatokines, such as selenoprotein P, angiopoietin-like protein 4 (ANGPTL4), and leukocyte cell-derived chemotaxin 2 (LECT2). We also assess the biology and molecular mechanisms of hepatokines in the context of their potential as therapeutic targets for metabolic disorders and cardiovascular diseases.

KW - Angiopoietin-like protein 4

KW - Fetuin-A

KW - Fibroblast growth factor 21

KW - Hepatokine

KW - Leukocyte cell-derived chemotaxin 2

KW - Selenoprotein P

UR - http://www.scopus.com/inward/record.url?scp=84960908819&partnerID=8YFLogxK

U2 - 10.1016/j.bbacli.2016.03.002

DO - 10.1016/j.bbacli.2016.03.002

M3 - Review article

AN - SCOPUS:84960908819

SN - 2214-6474

VL - 5

SP - 108

EP - 113

JO - BBA Clinical

JF - BBA Clinical

ER -

Implication of hepatokines in metabolic disorders and cardiovascular diseases

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this